You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
News on CRISPR, gene editing, RNAi in genetics, genomics, and molecular diagnostics.
Sanyou will use the cell line in the development of preclinical antibody drug projects and to support its customers' human biotherapeutic products.
Vivlion, which also holds a license to Goethe University Frankfurt's CRISPR technology, will use the license to offer R&D reagents and screening services.
Researchers are hoping to make the technology a success for the environment and human health while avoiding the biases that resulted from the debate over GMOs.
The researchers created a test-on-a-chip technology that takes about 35 minutes to produce a result, and may partner with Ford to produce the chips.
The company will use the funding to expand its gene editing systems for potential therapeutic use, and to advance research and validation for its pipeline.
The UK has given emergency authorization for Pfizer and BioNTech's SARS-CoV-2 vaccine, the Associated Press reports.
A US advisory committee says healthcare workers and nursing home residents should be prioritized to receive a SARS-CoV-2 vaccine, according to the Financial Times.
The Wall Street Journal reports North Korean hackers have targeted half a dozen companies developing SARS-CoV-2 vaccines.
In Cell this week: long-term SARS-CoV-2 shedding, examination of the effects of a coronavirus spike protein mutation, and more.
CRISPR has developed into a core tool to facilitate genome editing, inspiring transformative ideas in engineering biology.